Ultragenyx Pharmaceutical | RARE - Operating Expenses


Ultragenyx Pharmaceutical reported $289M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Immunic USD 23.33M 2.67M Dec/2025
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Kyowa Hakko Kirin JPY 122.9B 13.95B Jun/2026
MacroGenics USD 21.2M 32.13M Mar/2026
Moderna USD 960M 817M Jun/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026